Haemonetics
172 hedge funds and large institutions have $2.03B invested in Haemonetics in 2014 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 56 increasing their positions, 69 reducing their positions, and 18 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
22% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 18
9% more capital invested
Capital invested by funds: $1.86B → $2.03B (+$167M)
1.93% more ownership
Funds ownership: 103.61% → 105.54% (+1.9%)
1% more funds holding
Funds holding: 170 → 172 (+2)
19% less repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 69
Top Buyers
Top Sellers
HAE Hedge Fund Activity: Q4 2014 in Review
172 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q4 2014, worth a combined $2.03B — up 9% from $1.86B a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new HAE positions and 18 closed out — a net gain of 4 holders — while 56 added to existing stakes and 69 trimmed.
The largest buyer was Westwood Holdings Group, adding an estimated $20.7M. The largest seller was Barrow, Hanley, Mewhinney & Strauss, cutting an estimated $18.1M.
- 172 institutional investors held Haemonetics (HAE) as of Q4 2014, up from 170 in Q3 2014.
- Funds reported $2.03B of Haemonetics stock for Q4 2014, up 9% quarter-over-quarter.
- 22 funds opened new Haemonetics positions in Q4 2014 and 18 closed out, a net change of +4 holders.
- The largest Haemonetics buyer in Q4 2014 was Westwood Holdings Group, an estimated $20.7M added.
- The largest Haemonetics seller in Q4 2014 was Barrow, Hanley, Mewhinney & Strauss, an estimated $18.1M sold.
Based on aggregated 13F filings for Q4 2014.